NEW YORK ( TheStreet) -- Bio-Reference Labs (Nasdaq: BRLI) hit a new 52-week high Thursday as it is currently trading at $24.49, above its previous 52-week high of $24.48 with 234,207 shares traded as of 4 p.m. ET. Average volume has been 223,400 shares over the past 30 days.

Bio-Reference has a market cap of $637 million and is part of the health care sector and health services industry. Shares are up 28.1% year to date as of the close of trading on Wednesday.

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. The company has a P/E ratio of 17.3, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Bio-Reference as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. You can view the full Bio-Reference Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.